可见的氨基乙酰丙酸诱导荧光是否为组织学确诊(世界卫生组织2016分类)低级别胶质瘤预后的独立生物标志物?
研究连续纳入74例组织学确诊为低级别胶质瘤(世界卫生组织2016分类)的患者,术中给予5-氨基乙酰丙酸(5-ALA)并活检荧光组织,分析荧光与无进展生存期、无恶性转化生存期和总生存期的关系。结果显示16例(21.6%)肿瘤发出荧光,荧光与较短的恶性转化生存期和总生存期独立相关,但与无进展生存期无独立预测关系。
要点
- 74例低级别胶质瘤中16例(21.6%)在5-ALA后显示可见荧光。
- 荧光组无恶性转化生存期和总生存期均短于无荧光组,且为独立预测因素。
- 荧光对无进展生存期无独立预测作用,IDH突变状态显著预测三项生存终点。
核心结论
- 荧光似乎是低级别胶质瘤固有恶性转化和总生存期的标志物,独立于已知预后标志物。
- 作者认为在决定辅助治疗时可将低级别胶质瘤的荧光情况纳入考虑。
研究设计与样本
- 连续纳入74例组织学确诊的低级别胶质瘤(世界卫生组织2016分类)患者,术中给予5-ALA并对荧光组织进行针对性活检。
- 将肿瘤大小、年龄、Karnofsky指数、对比增强、荧光及分子因素与无进展生存期、无恶性转化生存期和总生存期进行关联分析。
主要发现
- 74例低级别胶质瘤中16例(21.6%)发出荧光。
- 荧光与磁共振成像上的弱强化和正电子发射断层扫描PET-FET摄取增高部分相关,但与Karnofsky功能状态评分、肿瘤大小或年龄无关。
- 分子标志物中仅EGFR表达存在边缘差异(荧光组 vs 无荧光组:19% vs 5%;P = .057)。
- 中位随访46.4个月(95%置信区间[CI]:41.8-51.1)。
- 荧光组无进展生存期、无恶性转化生存期和总生存期均更短:无进展生存期中位9.8个月(95%CI:1.00-27.7)vs 45.8个月(31.9-59.7);无恶性转化生存期43.0个月(27.5-58.5)vs 64.6个月(57.7-71.5),中位未达到,P = .015;总生存期51.6个月(34.8-68.3)vs 68.2个月(62.7-73.8),P = .002。
关键数值与推荐
- 多因素分析中IDH状态和荧光均独立预测无恶性转化生存期和总生存期。
- 无进展生存期未被荧光独立预测。
- IDH突变显著预测无进展生存期、无恶性转化生存期和总生存期。
临床怎么用
- 作者认为荧光似乎是低级别胶质瘤固有恶性转化和总生存期的标志物,独立于已知预后标志物。
- 作者认为在决定辅助治疗时可将低级别胶质瘤的荧光情况纳入考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 20% of low-grade gliomas (LGG) display visible protoporphyrin fluorescence during surgery after 5-aminolevulinic acid (5-ALA) administration. OBJECTIVE: To determine if fluorescence represents a prognostic marker in LGG. METHODS: Seventy-four consecutive patients with LGG (World Health Organization 2016) were operated on with 5-ALA. Fluorescent tissue was specifically biopsied. Tumor size, age, Karnofsky index, contrast-enhancement, fluorescence, and molecular factors (IDH1/IDH2-mutations, Ki67/MIB1 Index, 1p19q codeletions, ATRX, EGFR, p53 expression, and O6-methylguanine DNA methyltransferase promotor methylation), were related to progression-free survival (PFS), malignant transformation-free survival (MTFS) and overall survival (OS). RESULTS: Sixteen of seventy-four LGGs (21.6%) fluoresced. Fluorescence was partially related to weak enhancement on magnetic resonance imaging and increased (positron emission tomography)PET-FET uptake, but not to Karnofsky Performance Score, tumor size, or age. Regarding molecular markers, only EGFR expression differed marginally (fluorescing vs nonfluorescing: 19% vs 5%; P = .057). Median follow-up was 46.4 mo (95% confidence interval [CI]: 41.8-51.1). PFS, MTFS, and OS were shorter in fluorescing tumors (PFS: median 9.8 mo, 95% CI: 1.00-27.7 vs 45.8, 31.9-59.7, MTFS: 43.0 [27.5-58.5] vs 64.6 [57.7-71.5], median not reached, P = .015; OS: 51.6, [34.8-68.3] vs [68.2, 62.7-73.8], P = .002). IDH mutations significantly predicted PFS, MTFS, and OS. In multivariate analysis IDH status and fluorescence both independently predicted MTFS and OS. PFS was not independently predicted by fluorescence. CONCLUSION: This is the first report investigating the role of ALA-induced fluorescence in histologically confirmed LGG. Fluorescence appeared to be a marker for inherent malignant transformation and OS, independently of known prognostic markers. Fluorescence in LGG might be taken into account when deciding on adjuvant therapies.
引用
- Jaber M, Ewelt C, Wölfer J, et al. Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas? Neurosurgery. 2019. PMID: 30107580. doi:10.1093/neuros/nyy365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。